Eckert & Ziegler stock (DE0005659700): Nuclear medicine supplier in focus after latest quarterly figures

Eckert & Ziegler has reported new quarterly figures and updated its outlook, keeping the specialist for radioactive components in the spotlight of nuclear medicine investors. What drives the business – and what US-focused investors should know.

Eckert & Ziegler has recently released new quarterly figures and confirmed its role as a specialized supplier for nuclear medicine and industrial radiation applications, drawing fresh attention from investors focused on medical technology and healthcare suppliers. The company’s latest report highlighted the contribution of radioisotopes for cancer diagnostics and therapy as key revenue drivers, according to company disclosures and financial updates published in the current reporting season.

In the most recent quarter reported in 2026, Eckert & Ziegler presented sales and earnings data that underscored the importance of its nuclear medicine segment, while also commenting on ongoing investments in production capacity and regulatory-compliant manufacturing sites. Management reiterated that demand from oncology imaging and radiopharmaceutical therapy partners remains structurally supported by demographic trends and the growing adoption of targeted cancer treatments in hospitals and clinics worldwide.

As of: 26.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Eckert & Ziegler Strahlentechnik
• Sector/industry: Medical technology, nuclear medicine, industrial radiation
• Headquarters/country: Berlin, Germany
• Core markets: Europe, North America and selected Asia-Pacific regions
• Key revenue drivers: Radioisotopes and components for diagnostics and therapy in nuclear medicine; industrial radiation technology products
• Home exchange/listing venue: Xetra and regional German exchanges (ticker: EUZ)
• Trading currency: Euro (EUR)

Eckert & Ziegler: core business model

Eckert & Ziegler operates as a niche supplier within the broader healthcare and industrial technology ecosystem, focusing on radioactive components and services. The group’s core competence lies in producing, processing and packaging radioisotopes that are used as inputs for diagnostic imaging, cancer therapy and industrial measurement solutions. Through this role, the company positions itself as a crucial supplier rather than a fully integrated pharmaceutical or device manufacturer.

In nuclear medicine, Eckert & Ziegler supplies radioisotopes and related components to radiopharmaceutical companies, clinics and research institutions. These customers use the materials in radiolabeled drugs, imaging tracers and therapeutic applications that target tumors with precision radiation. The company benefits from long qualification cycles, strict regulatory frameworks and the need for reliable, high-quality radioactive materials, which can create relatively stable customer relationships and recurring demand.

Beyond healthcare, the company also addresses industrial applications where radiation sources are required for measurement, testing and quality control. These include density and level measurement in industrial processes, material testing and calibration services. While this industrial segment is typically smaller than nuclear medicine in terms of growth prospects, it can provide diversification against fluctuations in healthcare-related demand and changes in reimbursement systems.

The business model is anchored in specialized production facilities that must comply with radiation safety, environmental and pharmaceutical-grade standards. These plants are capital-intensive and subject to regulatory inspections, but once established, they can represent significant barriers to entry for potential competitors. As a result, Eckert & Ziegler combines elements of a healthcare supplier, a regulated manufacturer and an industrial technology company in one corporate structure.

Main revenue and product drivers for Eckert & Ziegler

One of the key revenue drivers for Eckert & Ziegler is the production of radioisotopes for diagnostic imaging in oncology and cardiology. Hospitals and imaging centers increasingly rely on PET and SPECT procedures, which require short-lived isotopes that must be produced and delivered within tight time windows. Eckert & Ziegler participates in this value chain by providing generator systems, targets and other components that enable clinical and industrial partners to supply radiopharmaceuticals to end users.

Another important pillar is the therapeutic side of nuclear medicine, often referred to as radioligand or targeted radionuclide therapy. These treatments pair a radioactive isotope with a targeting molecule to concentrate radiation directly in tumor tissue while sparing healthy tissue as much as possible. For this segment, Eckert & Ziegler typically supplies the radioactive component, which must meet strict purity and safety specifications. As pipelines of radiopharmaceutical companies progress and more therapies receive approvals, the underlying demand for high-quality isotopes can increase.

Industrial radiation technology provides a further source of revenue. Products used for nondestructive testing, level measurement and process control rely on stable and reliable radiation sources. Customers in sectors such as chemicals, oil and gas, and manufacturing may use these solutions to monitor production processes and validate quality standards. This business is less dependent on healthcare reimbursement debates and instead follows cycles in capital expenditures and industrial activity.

In addition to product sales, services such as source recycling, calibration, logistics solutions for radioactive materials and regulatory support can contribute to revenue and customer stickiness. Handling and transporting radioactive products requires specialized know-how and certifications, and many customers prefer one-stop solutions that cover both materials and associated services. This service component can also help stabilize revenue over time.

Industry trends and competitive position

Nuclear medicine is experiencing a period of renewed attention as targeted therapies and advanced diagnostic imaging expand. Demographic trends such as aging populations and a rising incidence of cancer increase the global need for accurate diagnostics and effective treatments. Eckert & Ziegler is positioned in the supply chain as a provider of essential inputs rather than finished drugs, which exposes it indirectly to these growth drivers while limiting direct exposure to drug pricing debates.

The competitive landscape in radioisotope production is shaped by a relatively small number of specialized players that operate nuclear reactors, cyclotrons or highly regulated processing facilities. Barriers to entry include high upfront investments, long development and qualification cycles, and complex safety and regulatory requirements. Within this environment, Eckert & Ziegler competes on reliability, product quality, regulatory track record and the ability to offer tailored solutions for pharmaceutical and industrial customers.

At the same time, the industry faces challenges such as ensuring stable access to reactor capacity, modernizing aging infrastructure and managing geopolitical and regulatory uncertainties around nuclear technologies. Companies must navigate shifting expectations from regulators and healthcare authorities regarding safety, environmental protection and supply security. For Eckert & Ziegler, maintaining diversified sourcing strategies and investing in modern facilities can be key elements of its competitive positioning.

Why Eckert & Ziegler matters for US investors

For US-based investors, Eckert & Ziegler represents an opportunity to gain exposure to the nuclear medicine supply chain through a European-listed company. Many of the radiopharmaceutical and biotech customers served by the company operate globally and include partners or competitors that are listed on US exchanges. As a result, the stock can function as a complementary holding for investors following oncology, imaging and medtech themes on both sides of the Atlantic.

The company’s relevance for US investors is also linked to the growing adoption of targeted radiopharmaceutical therapies in the United States. As more treatments receive approval from US regulators and enter clinical practice, demand for high-quality isotopes and related components can rise. Even though Eckert & Ziegler is headquartered in Germany, its customer base and industry exposure are inherently international, including activities and partnerships that touch the US healthcare market.

However, US investors need to consider factors such as trading in euros, listing on German exchanges and the influence of European regulatory and tax frameworks. Currency fluctuations between the US dollar and the euro can affect the value of investments when measured in US dollars. In addition, time zone differences and local market practices play a role in liquidity patterns and news flow timing, which may be relevant for active investors and traders.

Conclusion

Eckert & Ziegler stands at the intersection of nuclear medicine, medical technology and industrial radiation applications, supplying critical radioisotope-based components to partners around the world. The latest quarterly figures highlight how demand from oncology imaging and targeted therapies continues to shape the company’s revenue profile, while industrial products provide additional diversification. For US investors following healthcare innovation and medtech supply chains, the stock offers an indirect way to participate in the expansion of radiopharmaceutical diagnostics and therapies, combined with the specific opportunities and risks of a euro-denominated, Germany-listed share.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.